By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arbitrators have sided with Exiqon, allowing it to market locked nucleic acid-based LNA amidites and LNA oligonucleotides to the pharmaceutical market, the Danish firm announced today.

The decision by an arbitration court ends proceedings initiated by Exiqon last year against Santaris Pharma in a dispute over the LNA products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.